StreetAlpha.app
Home › Stocks › IFRX

InflaRx N.V. (IFRX)

Healthcare
$1.15
▼ −2.54%
LAST CLOSE · NOV 17

InflaRx develops drugs that block the inflammatory protein C5a, with vilobelimab sold to hospitals for COVID-19 patients. It last closed at $1.15 on Nov 17, down 2.54% on the day. In the past 30 days there were 1 dark pool print totaling $408K, the largest $408K.

AI Auto Pilots
Is IFRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
EUR 29K
−82.3% vs a year ago
Net income
−EUR 45.6M
−155582.1% margin
Gross margin
−24677.9%
−EUR 7.2M gross profit
Balance sheet
Cash & equivalents
EUR 16.0M
At Dec 31
Shareholder equity
EUR 41.6M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: EUR 63KEUR 63KFY2023FY2024: EUR 166KEUR 166KFY2024FY2025: EUR 29KEUR 29KFY2025

From IFRX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 20). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated IFRX in the past 90 days, not enough for a consensus
Average 12-month target
$8.00
▲ 595.7% upside

Based on 1 analyst who set a price target on IFRX in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $1.15.

Low $8.00Avg $8.00High $8.00
Blue marker: last close $1.15
Highest target$8.00
Average target$8.00
Lowest target$8.00
Latest rating changes
NeedhamInitiated
Sep 14Buy$8
Cantor FitzgeraldMaintained
Aug 7Buy$6
Raymond JamesUpgrade
May 13Buy$9
DateFirmActionRatingPrice target
Sep 14NeedhamInitiatedBuy$8
Aug 7Cantor FitzgeraldMaintainedBuy$6
May 13Raymond JamesUpgradeBuy$9
Loading…

Technical Analysis

IFRX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 26% below its 20 day and 44% below its 50 day average. It is 44% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the Pivot at $1.14, and the nearest resistance the Pivot R1 at $1.20.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 11.1%/day
Key levels
$2.9552 week high+156.5%
$1.84100 day average+60.0%
$1.66200 day average+44.3%
$1.6550 day average+43.5%
$1.61Swing high (Oct 20)+40.0%
$1.4520 day average+26.1%
$1.20Pivot R1+4.3%
$1.15Last close
$1.14Pivot−0.9%
$1.09Pivot S1−5.2%
$0.8052 week low−30.4%
Indicators
RSI (14)30.79Weak, oversold below 30Neutral
MACD-0.14Below its signal lineBearish
Stochastic5.7Near the bottom of its rangeOversold
ADX (14)31.1Trending down
Williams %R-90.8Oversold below −80, overbought above −20Oversold
CCI (20)-108.6Oversold below −100, overbought above 100Oversold
Rate of change−29.0%Change over 10 sessionsBearish
ATR (14)$0.13Typical daily range, 11.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IFRX

What happened before

See how IFRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IFRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IFRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IFRX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$408K
Largest print
$408K
Loading…

IFRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲35 buying vs 22 selling
  • ▲Shares held by funds +3.5%
  • ▲Funds holding +2
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding6462+3.2%
In funds' top 1000–
Held by funds–––
New / increased12 / 2330 / 13−18.6%
Reduced / sold out13 / 97 / 3+120.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IFRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IFRX is in one of them and how their past IFRX trades turned out.

IFRX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IFRX in an article yet. Here's the latest on the wider market.

About InflaRx N.V.

InflaRx is a biopharmaceutical company based in Jena, Germany, that develops treatments aimed at blocking C5a, a protein that drives inflammation. Its approved product, vilobelimab, is given intravenously and is sold in the U.S. under the name GOHIBIC, where hospitals can order it for critically ill COVID-19 patients. Its lead candidate, izicopan, is taken by mouth and is being studied for chronic skin conditions such as hidradenitis suppurativa and chronic spontaneous urticaria.

Headquarters
Jena, Germany